Anticipated Impact of Stem Cell and Other Cellular Medicine Clinical Trials for COVID-19
- 11 June 2021
- journal article
- research article
- Published by Taylor & Francis in Regenerative Medicine
- Vol. 16 (6) , 525-533
Abstract
Aim: There is a critical need for safe and effective treatments for COVID-19. One possible type of treatment is cellular medicine such as stem cell therapy, but its potential is unclear. Here, our ...Keywords
This publication has 17 references indexed in Scilit:
- Cell-based therapies for coronavirus disease 2019: proper clinical investigations are essentialCytotherapy, 2020
- Against pandemic research exceptionalismScience, 2020
- A Phase 3, Single-Arm, Prospective Study of Remestemcel-L, Ex Vivo Culture-Expanded Adult Human Mesenchymal Stromal Cells for the Treatment of Pediatric Patients Who Failed to Respond to Steroid Treatment for Acute Graft-versus-Host DiseaseTransplantation and Cellular Therapy, 2020
- Current status of cell-based therapies for respiratory virus infections: applicability to COVID-19European Respiratory Journal, 2020
- Transplantation of ACE2- Mesenchymal Stem Cells Improves the Outcome of Patients with COVID-19 PneumoniaAging and disease, 2020
- Too Much Carrot and Not Enough Stick in New Stem Cell Oversight TrendsCell Stem Cell, 2018
- Balancing Safety and Innovation for Cell-Based Regenerative MedicineNew England Journal of Medicine, 2018
- Selling Stem Cells in the USA: Assessing the Direct-to-Consumer IndustryCell Stem Cell, 2016
- Challenges in the translation and commercialization of cell therapiesBMC Biotechnology, 2015
- Safety of Cell Therapy with Mesenchymal Stromal Cells (SafeCell): A Systematic Review and Meta-Analysis of Clinical TrialsPLOS ONE, 2012